QR Code

Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials

Background Lebrikizumab, a high-affinity monoclonal antibody targeting IL-13, previously demonstrated clinical efficacy in three randomized, double-blind, placebo-controlled Phase 3 trials that included adults and adolescents with moderate-to-severe atopic dermatitis (AD): ADvocate1, ADvocate2, and...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Adelaide A. Hebert, Carsten Flohr, H. Chih-ho Hong, Alan D. Irvine, Evangeline Pierce, Hany Elmaraghy, Sreekumar Pillai, Zach Dawson, Sherry Chen, Clara Armengol, Elaine Siegfried, Stephan Weidinger
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Taylor & Francis Group 2024-12-01
Rangatū:Journal of Dermatological Treatment
Ngā marau:
Adolescents
atopic dermatitis
lebrikizumab
efficacy
quality of life
Urunga tuihono:https://www.tandfonline.com/doi/10.1080/09546634.2024.2324833
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite